1
|
Wada T, Mori-Anai K, Takahashi A, Matsui T, Inagaki M, Iida M, Maruyama K, Tsuda H. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study in Japan. J Diabetes Investig 2022; 13:1981-1989. [PMID: 35861630 DOI: 10.1111/jdi.13888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 07/12/2022] [Accepted: 07/19/2022] [Indexed: 11/28/2022] Open
Abstract
AIMS/INTRODUCTION The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial has demonstrated the effects of canagliflozin on preventing clinically important kidney outcomes in patients with type 2 diabetes mellitus and chronic kidney disease; however, not many Japanese patients were included in the trial. The present study evaluated the efficacy and safety of canagliflozin in Japanese chronic kidney disease patients with type 2 diabetes mellitus. MATERIALS AND METHODS In this multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study, chronic kidney disease patients with type 2 diabetes mellitus were randomly assigned to receive either 100 mg canagliflozin or a matching placebo once daily for 104 weeks. The primary efficacy endpoint was the incidence of a 30% decline in estimated glomerular filtration rate. RESULTS Overall, 308 patients were randomized to the canagliflozin (n = 154) and placebo (n = 154) groups. The incidence of a 30% decline in estimated glomerular filtration rate at Week 104 was 18.2% and 29.5%, respectively, and the point estimate of the intergroup difference (placebo - canagliflozin) was 11.3% (95% confidence interval, 1.2-21.5, P = 0.029), which was significant. The overall incidence of adverse events was similar in the two groups. CONCLUSIONS This study suggests that canagliflozin safely reduces the risk of end-stage renal disease in Japanese chronic kidney disease patients with type 2 diabetes mellitus. CLINICALTRIALS gov (NCT03436693).
Collapse
Affiliation(s)
- Takashi Wada
- Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
| | - Kazumi Mori-Anai
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Akiko Takahashi
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Takahiro Matsui
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
| | - Masaya Inagaki
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Mitsutaka Iida
- Quality & Vigilance Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Ken Maruyama
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| | - Hidetaka Tsuda
- Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan
| |
Collapse
|
2
|
Wada T, Mori‐Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M, Arakawa K, Jardine MJ. Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial. J Diabetes Investig 2022; 13:54-64. [PMID: 34212533 PMCID: PMC8756319 DOI: 10.1111/jdi.13624] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 06/23/2021] [Accepted: 06/27/2021] [Indexed: 11/28/2022] Open
Abstract
AIMS/INTRODUCTION The sodium-glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post-hoc analysis to evaluate the efficacy and safety of canagliflozin in a subgroup of participants in East and South-East Asian (EA) countries who are at high risk of renal complications. MATERIALS AND METHODS Participants with an estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio of >300-5,000 mg/g were randomized to 100 mg of canagliflozin or a placebo. The effects of canagliflozin treatment on pre-specified efficacy and safety outcomes were examined using Cox proportional hazards regression between participants from EA countries (China, Japan, Malaysia, the Philippines, South Korea and Taiwan) and the remaining participants. RESULTS Of 4,401 participants, 604 (13.7%) were from EA countries; 301 and 303 were assigned to the canagliflozin and placebo groups, respectively. Canagliflozin lowered the risk of primary outcome (composite of end-stage kidney disease, doubling of serum creatinine level, or renal or cardiovascular death) in EA participants (hazard ratio 0.54, 95% confidence interval 0.35-0.84). The effects of canagliflozin on renal and cardiovascular outcomes in EA participants were generally similar to those of the remaining participants. Safety outcomes were similar between the EA and non-EA participants. CONCLUSIONS In the CREDENCE trial, the risk of renal and cardiovascular events was safely reduced in participants from EA countries at high risk of renal events.
Collapse
Affiliation(s)
- Takashi Wada
- Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical SciencesKanazawa UniversityKanazawaJapan
| | - Kazumi Mori‐Anai
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Yutaka Kawaguchi
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Hideyuki Katsumata
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationOsakaJapan
| | - Hidetaka Tsuda
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Mitsutaka Iida
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Kenji Arakawa
- Ikuyaku. Integrated Value Development DivisionMitsubishi Tanabe Pharma CorporationTokyoJapan
| | - Meg J Jardine
- The George Institute for Global Health, UNSWSydneyAustralia
- NHMRC Clinical Trials CenterUniversity of SydneySydneyAustralia
- Concord Repatriation General HospitalSydneyAustralia
| |
Collapse
|
3
|
Ueo H, Ueo H, Minoura I, Gamachi A, Doi T, Yamaguchi M, Yamashita T, Tsuda H, Moriya T, Yamaguchi R, Kozuka Y, Sasaki T, Masuda T, Kai Y, Kubota Y, Urano Y, Mori M, Mimori K. Clinical usefulness of a novel fluorescence technique for the intraoperative diagnosis of surgical margins in patients with breast cancer. Br J Surg 2021; 108:e340-e342. [PMID: 34428279 DOI: 10.1093/bjs/znab265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 06/02/2021] [Accepted: 06/22/2021] [Indexed: 11/12/2022]
Abstract
In both 5- and 15-min data, FI was significantly higher in malignant tissues than in benign tissues. The diagnostic accuracy was similar at 5 and 15 min. Therefore, the 5-min FI was enough applying in the further analyses.
Collapse
Affiliation(s)
- H Ueo
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Ueo Breast Cancer Hospital, Oita, Japan
| | - H Ueo
- Ueo Breast Cancer Hospital, Oita, Japan
| | - I Minoura
- Goryo Chemical, Inc., Sapporo, Japan
| | - A Gamachi
- Department of Pathology, Almeida Memorial Hospital, Oita, Japan
| | - T Doi
- Breast Cancer Centre, Shonan Memorial Hospital, Kamakura, Japan
| | - M Yamaguchi
- Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan
| | - T Yamashita
- Department of Breast and Endocrine Surgery, Kanagawa Cancer Centre, Yokohama, Japan
| | - H Tsuda
- Department of Basic Pathology, National Defence Medical College, Tokorozawa, Japan
| | - T Moriya
- Department of Pathology, Kawasaki Medical School, Kurashiki, Japan
| | - R Yamaguchi
- Department of Pathology and Laboratory Medicine, Kurume University Medical Centre, Kurume, Japan
| | - Y Kozuka
- Department of Pathology, Mie University Hospital, Tsu, Japan
| | - T Sasaki
- Department of Next-Generation Pathology Information and Networking, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
| | - T Masuda
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan
| | - Y Kai
- Ueo Breast Cancer Hospital, Oita, Japan
| | - Y Kubota
- Ueo Breast Cancer Hospital, Oita, Japan
| | - Y Urano
- Graduate School of Medicine and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - M Mori
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan
| |
Collapse
|
4
|
Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Tsuda H, Sugiyama T. The first study evaluating the distribution of gBRCA1/2 variants within the ovarian cancer cluster region in Japanese ovarian cancer patients. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2020.05.632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Yotsumoto D, Osako T, Matsuura M, Takayama S, Kaneko K, Takahashi M, Shimazu K, Yoshidome K, Kuraoka K, Itakura M, Tani M, Ishikawa T, Ohi Y, Kinoshita T, Sato N, Tsujimoto M, Tsuda H, Nakamura S, Noguchi S, Akiyama F. 180P Development of prognosis prediction model using cytokeratin 19 mRNA copy number of sentinel lymph node metastasis in breast cancer: A multicenter study in Japan. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
6
|
Tsuda H, Komine M, Ohtsuki M. 365 Regulation of IL-33 gene expression by TNFα in normal human epidermal keratinocytes. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Fujikawa K, Hattori K, Tsuda H, Sugiyama T. The first nationwide Japanese multicenter study: Characterizing the cross-sectional approach to ovarian cancer genetic testing of (CHARLOTTE). Gynecol Oncol 2019. [DOI: 10.1016/j.ygyno.2019.04.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
8
|
Tsuda H, Komine M, Hioki T, Nakae S, Ohtsuki M. 072 IL-33 affects cytokine profile in psoriasis inflammation in imiquimod-induced psoriasis model mice. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Takehara K, Yamashita N, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Watanabe Y, Watanabe R, Teramoto N, Tsuda H, Saito T. Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese gynecologic oncology group. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Abdelgied M, El-Gazzar A, Alexander D, Alexander W, Numano T, Iigo M, Naiki A, Abdelhamid M, Takase H, Hirose A, Taquahashi Y, Kanno J, Takahashi S, Tsuda H. Potassium octatitanate fibers are possibly carcinogenic in male Fischer 344 rats. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
11
|
Tsuda H, Komine M, Ohtsuki M. 776 TNFα suppressed IL-33 expression induced by STAT1 and STAT3 dependent signal. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Kinoshita T, Takahashi M, Fujisawa T, Yamamoto N, Takanashi M, Aogi K, Hojo T, Yoshida M, Tsuda H. Radiofrequency ablation therapy for early-stage breast cancer: Results from 5 years of follow-up in a prospective multicenter study. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30413-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Miyashita M, Niikura N, Kumamaru H, Miyata H, Ishida T, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y. Abstract P2-11-11: Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: A study from the Japanese breast cancer registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-11-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Postmastectomy radiotherapy (PMRT) has been shown to be beneficial in node-positive breast cancer patients. However, the role of PMRT for patients receiving modern neoadjuvant chemotherapy (NAC) are controversial. We aimed to evaluate the efficacy of radiotherapy for breast cancer patients treated with NAC and mastectomy in the Japanese Breast Cancer Registry.
Methods:
Patients who received NAC and mastectomy for cT1-4 cN0-2 M0 breast cancer were included in this analysis. We assessed locoregional recurrence (LRR), distant disease-free survival (DDFS), and overall survival (OS) using the Kaplan-Meier method and compared them between the groups with and without PMRT by nodal status after NAC; ypN0, ypN1, and ypN2-3. We also performed multivariable cox regression analysis to evaluate the association of radiotherapy and these outcomes adjusting for baseline patient and cancer characteristics.
Results:
Of the 145,530 patients registered from 2004 to 2009, we identified 3,226 patients who met our inclusion criteria with the 5-year follow-up information including 1,299 ypN0, 1,036 ypN1, and 879 ypN2-3 cases. PMRT was performed in 185 patients (14.2%) with ypN0, 265 patients (25.6%) with ypN1, and 543 patients (61.8%) with ypN2-3. There was no difference in LRR, DDFS, and OS between the groups with and without radiotherapy for ypN1 patients who received NAC (P=0.72, P=0.29, and P=0.36, respectively). For patients with ypN2-3 breast cancer, radiotherapy significantly improved LRR (P<0.001), DDFS (P=0.01), and OS (P<0.001) on univariate analysis. No difference in LRR, DDFS, and OS was observed for ypN0 patients (P=0.81, P=0.15, and P=0.05, respectively). In multivariable analysis, the use of radiotherapy was independently associated with improved LRR [hazard ratio (HR): 0.608, 95% confidence interval (CI): 0.452–0.818, P=0.001] and OS [HR: 0.685, 95% CI: 0.531–0.885, P=0.004] for ypN2-3 patients.
Effect of PMRT on locoregional recurrence by the ypN subgroupsypN subgroupHazard ratio95%CI Low95%CI HighP valueypN00.8550.4581.5960.623ypN10.8320.5491.2620.387ypN2-30.6080.4520.8180.001
Effect of PMRT on overall survival by the ypN subgroupsypN subgroupHazard ratio95%CI Low95%CI HighP valueypN01.3250.8412.0870.224ypN10.8800.5991.2930.514ypN2-30.6850.5310.8850.004
Radiotherapy was not associated with OS among patients with ypN0 [HR: 1.325, 95% CI: 0.841–2.087, P=0.224] and ypN1 [HR: 0.880, 95% CI: 0.599–1.293, P=0.514]. There was no significant difference in DDFS with the addition of radiotherapy for all ypN subgroups.
Conclusions:
The results from this nationwide database study of breast cancer patients following modern NAC showed that PMRT did not improve survival for patients with ypN1 and ypN0. Radiotherapy might be only beneficial for ypN2-3 breast cancer patients who received NAC and mastectomy in the modern era. Randomized clinical trials are needed to optimize the use of PMRT for breast cancer patients treated with neoadjuvant chemotherapy.
Citation Format: Miyashita M, Niikura N, Kumamaru H, Miyata H, Ishida T, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y. Role of postmastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer patients: A study from the Japanese breast cancer registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-11-11.
Collapse
Affiliation(s)
- M Miyashita
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - N Niikura
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - H Kumamaru
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - H Miyata
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - T Ishida
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - T Kinoshita
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - H Tsuda
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - S Nakamura
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| | - Y Tokuda
- Graduate School of Medicine, Tohoku University; Tokai University School of Medicine; Graduate School of Medicine, Tokyo University; Keio University; National Cancer Center Hospital; National Defense Medical College; Showa University
| |
Collapse
|
14
|
Yoshioka Y, Yamamoto U, Tsuda H, Handa S, Yoshimura C, Tokunoh T, Nishizaka M, Ando SI. The factors that affect to the better compliance of mandibular advancement device when compared with continuous positive airway pressure in the patients with moderate to severe sleep apnea syndrome. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Wang QH, Ri S, Tsuda H, Kodera M, Suguro K, Miyashita N. Visualization and automatic detection of defect distribution in GaN atomic structure from sampling Moiré phase. Nanotechnology 2017; 28:455704. [PMID: 29039360 DOI: 10.1088/1361-6528/aa8d83] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Quantitative detection of defects in atomic structures is of great significance to evaluating product quality and exploring quality improvement process. In this study, a Fourier transform filtered sampling Moiré technique was proposed to visualize and detect defects in atomic arrays in a large field of view. Defect distributions, defect numbers and defect densities could be visually and quantitatively determined from a single atomic structure image at low cost. The effectiveness of the proposed technique was verified from numerical simulations. As an application, the dislocation distributions in a GaN/AlGaN atomic structure in two directions were magnified and displayed in Moiré phase maps, and defect locations and densities were detected automatically. The proposed technique is able to provide valuable references to material scientists and engineers by checking the effect of various treatments for defect reduction.
Collapse
Affiliation(s)
- Q H Wang
- Research Institute for Measurement and Analytical Instrumentation, National Institute of Advanced Industrial Science and Technology, 1-1-1 Umezono, Tsukuba, Ibaraki 305-8568, Japan
| | | | | | | | | | | |
Collapse
|
16
|
Tsuda H, Komine M, Ohtsuki M. 405 STAT3 activation causes IL-33 expression in normal human epidermal keratinocyte. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Okada H, Komine M, Tsuda H, Kamiya K, Ohtsuki M. 603 Expression of factors regulating cytokinesis in Bowen’s disease. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Demitsu T, Jinbu Y, Komine M, Umemoto N, Kakurai M, Yoneda K, Yamamoto A, Tsuda H, Ohtsuki M, Mori Y. 145 An ultrastructural study of familial type and non-familial type of white sponge nevus. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Jin M, Komine M, Tsuda H, Tominaga S, Ohtsuki M. 428 The double-stranded RNA induces IL-33 promoter activation through TLR3-IRF3 pathway, depending on EGF receptor activation in normal human epidermal keratinocytes. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Tsuda H, Oshio T, Komine M, Tominaga S, Ohtsuki M. 900 Nuclear IL-33 promotes wound healing by sustaining cell division and motility through regulating actin filament re-construction. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Kinoshita T, Ohtani S, Doihara H, Yamamoto N, Takahashi M, Fujisawa T, Aogi K, Hojo T, Asaga S, Yoshida M, Tsuda H. Abstract P3-13-17: A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-13-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As the management of breast carcinoma evolves toward less invasive treatments, the next step is the possibility of removing the primary tumor without surgery. The most promising noninvasive ablation technique is radiofrequency ablation (RFA), which can effectively kill tumor cells with a low complication rate. Our preliminary studies of RFA followed by standard surgical resection have indicated that this technique is effective for surgical ablation of small (≤ 2cm) breast tumors without extensive intraductal components (EIC).
Methods: To determine if RFA is oncologically and cosmetically appropriate for the local treatment of primary breast carcinoma, this multi-center prospective study used RFA as the sole local treatment of breast tumors ≤ 1.5cm in size on ultrasound and MRI. Exclusion criteria include receiving of preoperative chemotherapy, or the presence of invasive lobular carcinoma or invasive ductal carcinoma with suspicious EIC. After confirmation that the standard baseline core biopsy for diagnosis and measurement of tumors markers (ER, PgR, HER-2/neu expression and the presence of the Ki-67 proliferative marker) have been obtained, consent will be obtained and the patient scheduled RFA. All patients received adjuvant radiation therapy. The use and choice of systemic therapy will be based on the information from the baseline core biopsy. The first primary endpoints of this study is successful tumor ablation, as evidenced by negative findings on vacuum-assisted or core biopsies and imaging studies after RFA. The second primary endpoints is the incidence of procedure related adverse events. Forty patients with small tumors that are clearly identifiable and measurable by ultrasound and MRI were enrolled. The response to ablation was evaluated with both vacuum-assisted or core biopsies and imaging studies every 3 months during the first year. The long-term outcomes were assessed using quality of life measurement scales and imaging studies every 6 months thereafter through year 5.
Results: Of the 58 patients who participated in this study, 55 completed the protocol. In 48 of the 55 (87%) treated patients, successful tumor ablation, as determined by negative findings on vacuum-assisted or core biopsies and imaging studies, was confirmed. The remaining 7 patients with biopsies positive for residual tumor underwent surgical resection. There were no local or distant recurrences in treated 55 patients with a median follow up of 47 (range 36-73) months.
Conclusions: RFA can be safely used alone in patients with small breast tumors, provided that local tumor control must be regularly assessed by image-guided vacuum-assisted or core biopsies after ablation. RFA has several potential advantages over lumpectomy for the treatment of early stage breast cancer.
Citation Format: Kinoshita T, Ohtani S, Doihara H, Yamamoto N, Takahashi M, Fujisawa T, Aogi K, Hojo T, Asaga S, Yoshida M, Tsuda H. A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-17.
Collapse
Affiliation(s)
- T Kinoshita
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - S Ohtani
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - H Doihara
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - N Yamamoto
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - M Takahashi
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - T Fujisawa
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - K Aogi
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - T Hojo
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - S Asaga
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - M Yoshida
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| | - H Tsuda
- National Cancer Center Hospital, Tokyo, Japan; Hiroshima City Hiroshima Citizens Hospital; Okayama University Hospital; Chiba Cancer Center; Hokkaido Cancer Center; Gunma Prefectural Cancer Cente; Shikoku Cancer Center; National Cancer Center Hospital East; National Defense Medical College Hospital
| |
Collapse
|
22
|
Miyamoto M, Takano M, Iwaya K, Shinomiya N, Goto T, Kato M, Suzuki A, Aoyama T, Hitrata J, Nagaoka I, Tsuda H, Furuya K. High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers. Br J Cancer 2016; 116:e2. [PMID: 27832666 PMCID: PMC5355918 DOI: 10.1038/bjc.2016.371] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Affiliation(s)
- M Miyamoto
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan.,Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan
| | - M Takano
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - K Iwaya
- Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - N Shinomiya
- Department of Molecular Biology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - T Goto
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - M Kato
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - A Suzuki
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - T Aoyama
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - J Hitrata
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - I Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan
| | - H Tsuda
- Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - K Furuya
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| |
Collapse
|
23
|
Tsuda H, Alexander D, Alexander W, Abd Elgied M, Elgazzar A, Xu J, Numano T, Suzui M, Futakuchi M, Fukamachi K, Hirose A, Kanno J. Development of a mechanism based short-term assay protocol to test carcinogenicity of multiple wall carbon nanotubes (MWNCTs) in the rat. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.07.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Evans M, Murofushi T, Tsuda H, Mikami Y, Zhao N, Ochiai K, Kurita-Ochiai T, Yamamoto M, Otsuka K, Suzuki N. Combined effects of starvation and butyrate on autophagy-dependent gingival epithelial cell death. J Periodontal Res 2016; 52:522-531. [DOI: 10.1111/jre.12418] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/01/2016] [Indexed: 12/15/2022]
Affiliation(s)
- M. Evans
- Nihon University School of Dentistry; Tokyo Japan
| | - T. Murofushi
- Department of Biochemistry; Nihon University School of Dentistry; Tokyo Japan
| | - H. Tsuda
- Department of Biochemistry; Nihon University School of Dentistry; Tokyo Japan
- Division of Functional Morphology; Dental Research Center; Nihon University School of Dentistry; Tokyo Japan
| | - Y. Mikami
- Division of Microscopic Anatomy; Niigata University Graduate School of Medical and Dental Sciences; Niigata Japan
| | - N. Zhao
- Department of Biochemistry; Nihon University School of Dentistry; Tokyo Japan
- Department of Endodontics; School of Dentistry; Shandong University; Jinan Shandong China
| | - K. Ochiai
- Department of Oral Microbiology; Nihon University School of Dentistry; Tokyo Japan
- Divisions of Immunology and Pathobiology; Dental Research Center; Nihon University School of Dentistry; Tokyo Japan
| | - T. Kurita-Ochiai
- Department of Microbiology and Immunology; Nihon University School of Dentistry at Matsudo; Chiba Japan
| | - M. Yamamoto
- Department of Microbiology and Immunology; Nihon University School of Dentistry at Matsudo; Chiba Japan
| | - K. Otsuka
- Department of Biochemistry; Nihon University School of Dentistry; Tokyo Japan
- Division of Functional Morphology; Dental Research Center; Nihon University School of Dentistry; Tokyo Japan
| | - N. Suzuki
- Department of Biochemistry; Nihon University School of Dentistry; Tokyo Japan
- Division of Functional Morphology; Dental Research Center; Nihon University School of Dentistry; Tokyo Japan
| |
Collapse
|
25
|
Kiuchi J, Komatsu S, Ichikawa D, Aratani K, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Overexpression of CTEN relates to malignant outcome in adenocarcinoma of the esophagogastric junction. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61213-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
26
|
Ohashi T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Imamura T, Kiuchi J, Okamoto K, Tsuda H, Otsuji E. Overexpression of PBK/TOPK relates to tumor malignant potential and poor outcome of gastric carcinoma. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61052-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Jin M, Komine M, Tsuda H, Oshio T, Tominaga S, Ohtsuki M. 482 IL-33 is expressed in the lesional skin of herpes virus infection, but not of human papilloma virus infection. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Katagiri H, Kushida Y, Nojima M, Kuroda Y, Wakao S, Ishida K, Endo F, Kume K, Takahara T, Nitta H, Tsuda H, Dezawa M, Nishizuka SS. A Distinct Subpopulation of Bone Marrow Mesenchymal Stem Cells, Muse Cells, Directly Commit to the Replacement of Liver Components. Am J Transplant 2016; 16:468-83. [PMID: 26663569 DOI: 10.1111/ajt.13537] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Revised: 08/23/2015] [Accepted: 09/06/2015] [Indexed: 01/25/2023]
Abstract
Genotyping graft livers by short tandem repeats after human living-donor liver transplantation (n = 20) revealed the presence of recipient or chimeric genotype cases in hepatocytes (6 of 17, 35.3%), sinusoidal cells (18 of 18, 100%), cholangiocytes (15 of 17, 88.2%) and cells in the periportal areas (7 of 8, 87.5%), suggesting extrahepatic cell involvement in liver regeneration. Regarding extrahepatic origin, bone marrow mesenchymal stem cells (BM-MSCs) have been suggested to contribute to liver regeneration but compose a heterogeneous population. We focused on a more specific subpopulation (1-2% of BM-MSCs), called multilineage-differentiating stress-enduring (Muse) cells, for their ability to differentiate into liver-lineage cells and repair tissue. We generated a physical partial hepatectomy model in immunodeficient mice and injected green fluorescent protein (GFP)-labeled human BM-MSC Muse cells intravenously (n = 20). Immunohistochemistry, fluorescence in situ hybridization and species-specific polymerase chain reaction revealed that they integrated into regenerating areas and expressed liver progenitor markers during the early phase and then differentiated spontaneously into major liver components, including hepatocytes (≈74.3% of GFP-positive integrated Muse cells), cholangiocytes (≈17.7%), sinusoidal endothelial cells (≈2.0%), and Kupffer cells (≈6.0%). In contrast, the remaining cells in the BM-MSCs were not detected in the liver for up to 4 weeks. These results suggest that Muse cells are the predominant population of BM-MSCs that are capable of replacing major liver components during liver regeneration.
Collapse
Affiliation(s)
- H Katagiri
- Molecular Therapeutics Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
| | - Y Kushida
- Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - M Nojima
- Department of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Y Kuroda
- Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S Wakao
- Department of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - K Ishida
- Molecular Therapeutics Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
| | - F Endo
- Molecular Therapeutics Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
| | - K Kume
- Molecular Therapeutics Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan.,Institute for Biomedical Sciences, Iwate Medical University, Yahaba, Japan.,Medical Innovation by Advanced Science and Technology Program, Iwate Medical University, Morioka, Japan
| | - T Takahara
- Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
| | - H Nitta
- Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan
| | - H Tsuda
- Diagnostic Pathology Section, Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
| | - M Dezawa
- Department of Anatomy and Anthropology, Tohoku University Graduate School of Medicine, Sendai, Japan.,Department of Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - S S Nishizuka
- Molecular Therapeutics Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan.,Institute for Biomedical Sciences, Iwate Medical University, Yahaba, Japan.,Medical Innovation by Advanced Science and Technology Program, Iwate Medical University, Morioka, Japan.,Department of Surgery, Iwate Medical University School of Dentistry, Morioka, Japan.,Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Yahaba, Japan
| |
Collapse
|
29
|
Nishikawa T, Tanabe Y, Tsuda H, Yoshida M, Shimoi T, Shimomura A, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. 66P Predictive markers of clinical progressive disease during neoadjuvant chemotherapy in early triple negative breast cancers. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv519.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Hattori Y, Kotani T, Tsuda H, Mano Y, Tu L, Li H, Hirako S, Ushida T, Imai K, Nakano T, Sato Y, Miki R, Sumigama S, Iwase A, Toyokuni S, Kikkawa F. Maternal molecular hydrogen treatment attenuates lipopolysaccharide-induced rat fetal lung injury. Free Radic Res 2015; 49:1026-37. [PMID: 25947958 DOI: 10.3109/10715762.2015.1038257] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Maternal inflammation is associated with spontaneous preterm birth and respiratory impairment among premature infants. Recently, molecular hydrogen (H2) has been reported to have a suppressive effect on oxidative stress and inflammation. The aim of this study was to evaluate the effects of H2 on fetal lung injury caused by maternal inflammation. Cell viability and the production of interleukin-6 (IL-6) and reactive oxygen species (ROS) were examined by treatment with lipopolysaccharide (LPS) contained in ordinal or H2-rich medium (HM) using a human lung epithelial cell line, A549. Pregnant Sprague Dawley rats were divided into three groups: Control, LPS, and HW + LPS groups. Rats were injected with phosphate-buffered saline (Control) or LPS intraperitoneally (LPS) on gestational day 19 and provided H2 water (HW) ad libitum for 24 h before LPS injection (HW + LPS). Fetal lung samples were collected on day 20, and the levels of apoptosis, oxidative damage, IL-6, and vascular endothelial growth factor (VEGF) were evaluated using immunohistochemistry. The number of apoptotic cells, and levels of ROS and IL-6 were significantly increased by LPS treatment, and repressed following cultured with HM in A549 cells. In the rat models, the population positive for cleaved caspase-3, 8-hydroxy-2'-deoxyguanosine, IL-6, and VEGF was significantly increased in the LPS group compared with that observed in the Control group and significantly decreased in the HW + LPS group. In this study, LPS administration induced apoptosis and oxidative damage in fetal lung cells that was ameliorated by maternal H2 intake. Antenatal H2 administration may decrease the pulmonary mobility associated with inflammation in premature infants.
Collapse
Affiliation(s)
- Y Hattori
- Departments of Gynecology and Obstetrics, Nagoya University Graduate School of Medicine , Nagoya , Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Affiliation(s)
- T Tsuji
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - Y Itoh
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - T Nakamura
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - Y Toyozumi
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - N Arima
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| | - H Tsuda
- From the Division of Hematology/Oncology, Division of Neurology, Division of Nephrology and Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| |
Collapse
|
32
|
Hironaka A, Tsuda H, Yoshida M, Shimizu C, Tamura K, Fujiwara Y, Hojo T, Kinoshita T, Maeshima A, Hiraoka N. P019 Histopathological features of operable breast cancer detected in women younger than 35 years. Breast 2015. [DOI: 10.1016/s0960-9776(15)70069-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
33
|
Tanabe Y, Tsuda H, Yoshida M, Kinoshita T, Kodaira M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K. P025 Immunological factors to predict disease progression during neoadjuvant chemotherapy. Breast 2015. [DOI: 10.1016/s0960-9776(15)70075-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
34
|
Miyamoto M, Takano M, Iwaya K, Shinomiya N, Goto T, Kato M, Suzuki A, Aoyama T, Hirata J, Nagaoka I, Tsuda H, Furuya K. High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers. Br J Cancer 2015; 112:739-44. [PMID: 25628093 PMCID: PMC4333506 DOI: 10.1038/bjc.2015.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 11/29/2014] [Accepted: 12/22/2014] [Indexed: 12/11/2022] Open
Abstract
Background: High-temperature-required protein A2 (HtrA2), a protein relating with apoptosis in a caspases-dependent and non-dependent manner, has been reported to be associated with chemosensitivity in several human cancers. Methods: Tissue microarrays made from 142 patients with high-grade serous ovarian adenocarcinoma were evaluated to assess whether HtrA2 expression was related with several clinical parameters. Results: Negative HtrA2 expression was observed in 36 cases (25%) of the patients, and related with significantly lower response rates of primary chemotherapy than those with positive HtrA2 expression (56% vs 83%, P<0.01). In addition, negative HtrA2 expression was identified as an independent worse prognostic factor for progression-free survival and overall survival by multivariate analyses. Furthermore, HtrA2 downregulation modulated sensitivity to platinum in serous ovarian cancer cells in vitro. Conclusions: HtrA2 expression was a predictor for sensitivity to chemotherapy, and could be a candidate of molecular target in the treatment of high-grade serous ovarian cancers.
Collapse
Affiliation(s)
- M Miyamoto
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - M Takano
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - K Iwaya
- Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - N Shinomiya
- Department of Molecular Biology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - T Goto
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - M Kato
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - A Suzuki
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - T Aoyama
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - J Hirata
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - I Nagaoka
- Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan
| | - H Tsuda
- Department of Basic Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| | - K Furuya
- Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359-8513, Japan
| |
Collapse
|
35
|
Yoshihama T, Chiyoda T, Kataoka F, Nomura H, Iguchi Y, Hashimoto S, Yamagami W, Tominaga E, Susumu N, Tsuda H, Aoki D. Effectiveness of third-line chemotherapy in recurrent ovarian cancer patients. EUR J GYNAECOL ONCOL 2015; 36:424-427. [PMID: 26390696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
OBJECTIVE Despite recent advances in the treatment of recurrent ovarian cancer, little evidence exists describing the benefit of third- line chemotherapy. The present authors previously reported that the treatment-free interval (TFI) after second-line chemotherapy may predict a survival benefit of third-line chemotherapy, however the length of TFI was uncertain due to limited cases. In this study, the authors evaluated the length of TFI, which is correlated with the effectiveness of third-line chemotherapy and a prognostic factor of third-line chemotherapy. MATERIALS AND METHODS The authors reviewed the medical records of 85 women with recurrent ovarian cancer who received third-line chemotherapy after a paclitaxel/carboplatin (PC) regimen as first-line chemotherapy. RESULTS The response rate [complete response (CR) + partial response (PR)] and clinical benefit rate [(CBR): CR + PR + stable disease (SD)] during the TFI after second-line chemotherapy for 0-3 months, 3-6 months, and 6-12 months and ≥ 12 months were 9.8%, 0%, 0%, 43.8% and 15.7%, 50%, 66.7%, and 93.8%, respectively. The median overall survival (OS) from the onset of third-line chemotherapy was longer for TFI ≥ 3 months than for TFI 0-3 months (795 days vs. 281 days, p < 0.001). Finally, according to univariate (HR = 0.256; p < 0.001) and multivariate (HR = 0.264; p < 0.001) analyses, TFI was the independent significant prognostic factor for OS. CONCLUSIONS TFI less than three months after second-line chemotherapy may predict little survival benefit of third-line chemotherapy.
Collapse
|
36
|
Sakai K, Yamagami W, Susumu N, Nomura H, Kataoka F, Banno K, Tsuda H, Aoki D. Pathological factors associated with omental metastases in endometrial cancer. EUR J GYNAECOL ONCOL 2015; 36:397-401. [PMID: 26390690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE OF INVESTIGATION This study aimed to assess the role of omentectomy in the surgical therapy of endometrial cancer. MATERI- ALS AND METHODS: A retrospective study was performed in 98 patients who were pathologically diagnosed with endometrial cancer and had initially undergone surgical therapy at the present institution. This study analyzed the relationship between omental metastasis and clinicopathological factors. RESULTS Omental metastasis was detected in nine patients (9%). On univariate analysis, significant number of omental metastatic lesions were detected in few cases by positive peritoneal cytology, adnexal metastasis, gross dissemination, and lymphovascular space involvement. On multivariate analysis, adnexal metastasis were a significant risk factor. The sensitivity of the spe- cial histological type and the specificity of the macroscopic peritoneal dissemination and adnexal metastasis were all high. CONCLUSION Omentectomy plays a significant role in determining the exact surgical staging in cases with non-endometrioid cancer, adnexal metas- tasis, and macroscopic peritoneal dissemination.
Collapse
|
37
|
Komatsu S, Ichikawa D, Hirajima S, Nagata H, Nishimura Y, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Imoto I, Inazawa J, Otsuji E. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer 2014; 112:357-64. [PMID: 25321194 PMCID: PMC4453442 DOI: 10.1038/bjc.2014.543] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 09/01/2014] [Accepted: 09/18/2014] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND SET and MYND domain-containing protein 2 (SMYD2) is a lysine methyltransferase for histone H3, p53 and Rb and inhibits their transactivation activities. In this study, we tested whether SMYD2 (1q42) acts as a cancer-promoting factor by being overexpressed in gastric cancer. METHODS We analysed 7 gastric cancer cell lines and 147 primary tumor samples of gastric cancer, which were curatively resected in our hospital. RESULTS SET and MYND domain-containing protein 2 was detected in these cell lines (five out of seven cell lines; 71.4%) and primary tumor samples (fifty-six out of one hundred and forty-seven cases; 38.1%). Knockdown of SMYD2 using specific small interfering RNA inhibited proliferation, migration and invasion of SMYD2-overexpressing cells in a TP53 mutation-independent manner. Overexpression of SMYD2 protein correlated with larger tumor size, more aggressive lymphatic invasion, deeper tumor invasion and higher rates of lymph node metastasis and recurrence. Patients with SMYD2-overexpressing tumours had a worse overall rate of survival than those with non-expressing tumours (P=0.0073, log-rank test) in an intensity and proportion score-dependent manner. Moreover, multivariate analysis demonstrated that SMYD2 was independently associated with worse outcome (P=0.0021, hazard ratio 4.25 (1.69-10.7)). CONCLUSIONS These findings suggest that SMYD2 has a crucial role in tumor cell proliferation by its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in gastric cancer.
Collapse
Affiliation(s)
- S Komatsu
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - D Ichikawa
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - S Hirajima
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Nagata
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - Y Nishimura
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - T Kawaguchi
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - M Miyamae
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - W Okajima
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - T Ohashi
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Konishi
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - A Shiozaki
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Fujiwara
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - K Okamoto
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| | - H Tsuda
- Department of Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan
| | - I Imoto
- Department of Human Genetics, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8505, Japan
| | - J Inazawa
- Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113-5810, Japan
| | - E Otsuji
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
| |
Collapse
|
38
|
Kikuyama M, Akashi-Tanaka S, Hojo T, Kinoshita T, Ogawa T, Seto Y, Tsuda H. Utility of intraoperative frozen section examinations of surgical margins: implication of margin-exposed tumor component features on further surgical treatment. Jpn J Clin Oncol 2014; 45:19-25. [DOI: 10.1093/jjco/hyu158] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Tsuda H, Arima N. Sparganosis in follicular lymphoma patient. QJM 2014; 107:857-8. [PMID: 24652657 DOI: 10.1093/qjmed/hcu062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Tsuda
- Division of Haematology/Oncology, Kumamoto City Hospital, Kumamoto, Japan
| | - N Arima
- Division of Clinical Pathology, Kumamoto City Hospital, Kumamoto, Japan
| |
Collapse
|
40
|
Tsuda H, Saiki J. Memorizing slope but not elevation facilitates navigation in a virtual environment. J Vis 2014. [DOI: 10.1167/14.10.1351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
41
|
Hiramatsu K, Kawaguchi Y, Shimizu M, Sawaki N, Zheleva T, Davis RF, Tsuda H, Taki W, Kuwano N, Oki K. The Composition Pulling Effect in MOVPE Grown InGaN on GaN and AlGaN and its TEM Characterization. ACTA ACUST UNITED AC 2014. [DOI: 10.1557/s1092578300001320] [Citation(s) in RCA: 131] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
InGaN films have been grown on GaN and AlGaN epitaxial layers by metalorganic vapor phase epitaxy. The “composition pulling effect” during the initial InGaN growth stages has been studied as a function of the lattice mismatch between the InGaN and the underlying epitaxial layer. The crystalline quality of the InGaN is good near the InGaN/GaN interface and the composition is close to that of GaN. However, with increasing InGaN film thickness, the crystal quality deteriorates and the indium mole fraction increases. The composition pulling effect becomes stronger with increasing lattice mismatch. It is suggested that indium atoms are excluded from the InGaN lattice during the early growth stages to reduce the deformation energy from the lattice mismatch. TEM observations of the InGaN/GaN structure reveal that the degradation of the crystalline quality of InGaN films grown on GaN is caused by pit formation which arises from edge dislocations propagating through the InGaN film from the underlying GaN.
Collapse
|
42
|
Tsuda H, Takiwaki H. Comparison of on-site and photographic evaluations of the suppressive effects of cetirizine, loratadine, and fexofenadine on skin response to histamine lontophoresis: A double-blind, crossover study in healthy volunteers. Curr Ther Res Clin Exp 2014; 66:307-22. [PMID: 24672131 DOI: 10.1016/j.curtheres.2005.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2005] [Indexed: 10/25/2022] Open
Abstract
BACKGROUND The standard method used to determine the potency of antihistaminesis to assess the degree of suppression of skin response to histamine challenge. OBJECTIVES The aims of this study were to compare the efficacy of 3 antihistaminesusing a histamine challenge test and the usefulness of on-site evaluation with that of photographic evaluation of skin-test reactions. METHODS In this prospective, double-blind, crossover study, healthy volunteerswere given cetirizine 5 mg (CTZ-5) and 10 mg (CTZ-10), loratadine 10 mg (LOR), fexofenadine 60 mg BID (FEX), and placebo (PLC), in a randomly assigned order, with an interval of at least 1 week between treatments. Before and 0.5 to 24 hours after administration, the areas of flare and wheal induced by histamine iontophoresis were measured directly (on site) by 1 evaluator and by another evaluator using photographic images on a computer monitor. RESULTS Ten healthy volunteers (6 men, 4 women; mean age, 28.2 years[range, 20-39 years]; mean weight, 60.7 kg [range, 41-81 kg]) were enrolled. The data from 9 subjects were analyzed; the data from 1 subject were omitted because the subject used an over-the-counter cold medication containing diphenhydramine several times during the study. By both methods, all antihistamines were shown to suppress flare significantly from 4 to 24 hours after administration. CTZ was most potent in suppressing both flare and wheal. For flare, the areas as measured using on-site evaluation were larger overall than those measured using photographic evaluation, but the shapes of the time-course graphs were similar for both. Overall, the flare area measurements started to decrease significantly from baseline values 4 hours after drug administration, reached a nadir at 10.5 hours, and remained significantly lower compared with baseline values at 24 hours. Comparisons between antihistamines showed significant differences in mean flare areas between the 2 doses of CTZ and LOR from 8 to 12 hours after administration in both evaluation methods. The wheal areas were significantly reduced from baseline values by most of the antihistamines 4 to 12 hours after drug administration, reached their lowest values at 10.5 hours, and returned to near-baseline values at 24 hours. Comparisons with PLC values at each time point, however, showed significant differences only for CTZ-5 and CTZ-10 from 4 to 12 hours after administration. Comparison between antihistamines showed significant differences in mean flare areas between the 2 doses of CTZ and LOR from 8 to 12 hours after administration in both evaluation methods. Although the flare areas measured by both methods correlated linearly (r = 0.90; P < 0.001), the correlation for wheal areas was weaker (r = 0.76; P < 0.001). CONCLUSIONS In this study in healthy volunteers, single doses of CTZ 5 mg and CTZ 10 mg were more potent compared with single-dose LOR 10 mg and FEX 60 mg BID in suppressing skin response. Although linear correlations were found between skin-response areas, as measured by on-site and photographic evaluation, it was difficult to differentiate between wheal and flare by photographic evaluation, especially when a typical wheal was suppressed to slightly edematous erythema by antihistamines.
Collapse
Affiliation(s)
- Hidetaka Tsuda
- Department of Dermatology, School of Medicine, University of Tokushima,Tokushima, Japan
| | - Hirotsugu Takiwaki
- Department of Dermatology, School of Medicine, University of Tokushima,Tokushima, Japan
| |
Collapse
|
43
|
Sumigama S, Sugiyama C, Kotani T, Hayakawa H, Inoue A, Mano Y, Tsuda H, Furuhashi M, Yamamuro O, Kinoshita Y, Okamoto T, Nakamura H, Matsusawa K, Sakakibara K, Oguchi H, Kawai M, Shimoyama Y, Tamakoshi K, Kikkawa F. Uterine sutures at prior caesarean section and placenta accreta in subsequent pregnancy: a case-control study. BJOG 2014; 121:866-74; discussion 875. [DOI: 10.1111/1471-0528.12717] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/13/2014] [Indexed: 11/27/2022]
Affiliation(s)
- S Sumigama
- Department of Obstetrics and Gynaecology; Nagoya University Graduate School of Medicine; Aichi Japan
| | - C Sugiyama
- Department of Obstetrics and Gynaecology; Gifu Prefectural Tajimi Hospital; Gifu Japan
| | - T Kotani
- Department of Obstetrics and Gynaecology; Nagoya University Graduate School of Medicine; Aichi Japan
| | - H Hayakawa
- Department of Obstetrics and Gynaecology; Kasugai Municipal Hospital; Aichi Japan
| | - A Inoue
- Department of Obstetrics and Gynaecology; Hekinan Municipal Hospital; Aichi Japan
| | - Y Mano
- Department of Obstetrics and Gynaecology; Nagoya University Graduate School of Medicine; Aichi Japan
| | - H Tsuda
- Department of Obstetrics and Gynaecology; Nagoya University Graduate School of Medicine; Aichi Japan
| | - M Furuhashi
- Department of Obstetrics and Gynaecology; Japanese Red Cross Nagoya Daiichi Hospital; Aichi Japan
| | - O Yamamuro
- Department of Obstetrics and Gynaecology; Nagoya Daini Red Cross Hospital; Aichi Japan
| | - Y Kinoshita
- Department of Obstetrics and Gynaecology; Ogaki Municipal Hospital; Gifu Japan
| | - T Okamoto
- Department of Obstetrics and Gynaecology; Chukyo Hospital; Aichi Japan
| | - H Nakamura
- Department of Obstetrics and Gynaecology; Gifu Prefectural Tajimi Hospital; Gifu Japan
| | - K Matsusawa
- Department of Obstetrics and Gynaecology; Anjo Kosei Hospital; Aichi Japan
| | - K Sakakibara
- Department of Obstetrics and Gynaecology; Okazaki City Hospital; Aichi Japan
| | - H Oguchi
- Department of Obstetrics and Gynaecology; Toyota Memorial Hospital; Aichi Japan
| | - M Kawai
- Department of Obstetrics and Gynaecology; Toyohashi Municipal Hospital; Aichi Japan
| | - Y Shimoyama
- Department of Pathology and Laboratory Medicine; Nagoya University Hospital; Aichi Japan
| | - K Tamakoshi
- Department of Nursing; Nagoya University School of Health Sciences; Aichi Japan
| | - F Kikkawa
- Department of Obstetrics and Gynaecology; Nagoya University Graduate School of Medicine; Aichi Japan
| |
Collapse
|
44
|
Nakazono E, Miyazaki H, Abe S, Imai K, Masuda T, Iwamoto M, Moriguchi R, Ueno H, Ono M, Yazumi K, Moriyama K, Nakano S, Tsuda H. Discontinuation of leisure time impact-loading exercise is related to reduction of a calcaneus quantitative ultrasound parameter in young adult Japanese females: a 3-year follow-up study. Osteoporos Int 2014; 25:485-95. [PMID: 23794043 DOI: 10.1007/s00198-013-2416-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2012] [Accepted: 06/10/2013] [Indexed: 11/30/2022]
Abstract
UNLABELLED A 3-year follow-up study on 334 young Japanese females enrolled in a university at the age of 18 years revealed that discontinuation of leisure time impact-loading exercises performed in junior high and/or high school was associated with increased risk of reduction in calcaneus osteo-sono assessment index (OSI). INTRODUCTION Bone strength rapidly increases during puberty and reaches its peak by the end of adolescence. The aim of this study was to determine the lifestyle factors that influence the maintenance of calcaneus OSI in young adult females around the time when peak bone mass is attained. METHODS Annual health checkups including OSI measurements, anthropometrics, lifestyle analysis, and blood examination were performed 4 times on 334 Japanese females enrolled in a university at the age of 18 years. According to the slope of OSI change during the 3-year follow-up, the subjects were grouped into two categories: OSI loss (the lowest tertile) and OSI gain/stable (the second and third tertiles). RESULTS At the baseline assessment, the OSI loss group had higher OSI and height and an earlier menarche age than the OSI gain/stable group. Performing leisure time impact-loading exercise in junior high and/or high school but discontinuing it at university was associated with increased risk of OSI loss, independent of OSI, height and weight at the age of 18 years, weight change during follow-up, age of menarche, energy-adjusted nutrient intake, and alcohol drinking; the odds ratios were 4.1-4.9 compared with those performing impact-loading exercise at university. In particular, duration, frequency, and subjective intensity of impact-loading exercise during high school were positively associated with OSI loss. CONCLUSION Discontinuation of leisure time impact-loading exercises performed during late adolescence is associated with an increased risk of OSI loss in young adult females during the 3-year follow-up period.
Collapse
Affiliation(s)
- E Nakazono
- Graduate School of Health and Nutrition Sciences, Nakamura Gakuen University, 5-7-1, Befu, Jounan-ku, Fukuoka, 814-0198, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tanosaki R, Kumazawa T, Yoshida A, Oguni S, Nakano A, Yamagata S, Takahashi N, Kurosawa S, Kim SW, Yamashita T, Mori S, Heike Y, Fukuda T, Hamaguchi Y, Tsuda H. Novel and rapid enumeration method of peripheral blood stem cells using automated hematology analyzer. Int J Lab Hematol 2013; 36:521-30. [DOI: 10.1111/ijlh.12182] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Accepted: 09/17/2013] [Indexed: 11/28/2022]
Affiliation(s)
- R. Tanosaki
- Department of Blood Transfusion and Cellular Therapy; National Cancer Center Hospital; Tokyo Japan
| | - T. Kumazawa
- Department of Blood Transfusion and Cellular Therapy; National Cancer Center Hospital; Tokyo Japan
| | | | | | - A. Nakano
- Department of Pathology and Clinical Laboratories; National Cancer Center Hospital; Tokyo Japan
| | - S. Yamagata
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - N. Takahashi
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - S. Kurosawa
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - S. W. Kim
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - T. Yamashita
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - S. Mori
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - Y. Heike
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | - T. Fukuda
- Department of Hematology and Hematopoietic Stem Cell Transplantation; National Cancer Center Hospital; Tokyo Japan
| | | | - H. Tsuda
- Department of Pathology and Clinical Laboratories; National Cancer Center Hospital; Tokyo Japan
| |
Collapse
|
46
|
Tanabe Y, Tsuda H, Yamamoto H, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y. Abstract P5-08-12: Histopathological and immunohistochemical findings for epithelial-to-mesenchymal transition were associated with clinical progressive disease of triple-negative breast cancers during neoadjuvant chemotherapy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-08-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Clinical progressive disease (cPD) occurs during neoadjuvant therapy (NAC) in 3 to 5% of breast cancer patients. By gene expression profiling analyses using DNA microarray, the expression of epithelial-to-mesenchymal transition (EMT)-associated genes were shown to be correlated with chemoresistant phenotype of breast cancer cell lines. In order to reveal clinical implication of EMT-associated molecules on the acquisition of cPD property, we designed a retrospective histopathilogical and immunohistochemical case-control study. Patients and Methods: From pathology database of patients who received surgical resection, 86 patients with early triple-negative breast cancer (TNBC) were identified: 23 patients suffered cPD during NAC (PD group) and 63 control group patients did not receive NAC (C group), in whom >95% of patients was estimated to be non-PD group if NAC was performed. For these 86 cases, histopathological classification was performed and negativity of hormone receptors and HER2 was confirmed. As EMT markers, we immunohistochemically examined the expressions of vimentin, Twist, Twist NB and Snail. The chi-square test was used to assess statistically significant differences between the groups.Results: Histologically, PD group comprised 12 invasive ductal carcinomas (IDCs) (52%) and 11 metaplastic carcinomas (MPCs) (48%), and they all were nuclear grade 3. In C group, 52 (83%) were IDCs and 10 (16%) were histological types other than IDC or MPC, and there was only 1 MPC (1%) (p = 4.31E-08). Nuclear grade was 1, 2, and 3 in 1, 9, and 53, respectively. Vimentin was positive in cytoplasm of 74% of PD group and the incidence was higher than that in C group (49%) (p = 0.016). Cytoplasmic twist-2 and cytoplasmic and nuclear Snail expressions were detected almost equally between PD group and C group. Cytoplasmic Twist NB expression was more frequent in PD group (26%) than in C group (1.6%) (p = 0.0002). In PD group, a total of 17 cases comprising 9 MPCs and 8 IDCs, were positive for vimentin. In these 17 vimentin-positive cases, 14 were stable disease or partial response with an anthracyclin-containing regimen while all 16 patients receiving a taxane-containing regimen became cPD during the taxane-containing regimen.
Patient characteristics PD group (N = 23)Control group(N = 63)Age median (range)42(25-62)55(25-77)Clinical stage:I/II/III0/11/127/44/12Diagnosi at operation:IDC/MPC or MPC containing/others12/11/052/1/10Nuclear grade:1/2/30/0/231/9/53Tumor size at diagnosis4.8(2-14)2.8(1.2-12.0)Neoadjuvant chemoterapy regimen Anthracyclin containing:AC/CEF11/12-Taxane: paclitaxel/docetaxel20/2-
Conclusion: EMT features detected by metaplastic phenotype and cytoplasmic vimentin expression could be predictors for cPD during NAC for TNBC. The tumors of these phenotypes were likely to be resistant to a taxane-containing regimen.
Immunohistochemical profilingantibodyPD group (N = 23)Control group (N = 63)p-valueVimentin(cytoplasm)17 (74%)31 (49%)0.0411Twist-2(cytoplasm)21(91%)59 (94%)0.7849Snail-2(cytoplasm)12 (52%)38 (60%)0.5548Snail-2(nucleus)14 (61%)34 (54%)0.4677Twist NB(cyroplasm)6 (26%)1 (1.6%)0.0002
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-08-12.
Collapse
Affiliation(s)
| | - H Tsuda
- National Cancer Center Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Kido H, Kawawa Y, Manabe T, Nakajima Y, Iwamoto E, Tsuda H, Shimizu C, Kinoshita T, Kusumoto M, Arai Y. Utility of MRI and us for Evaluation of Minor Residual Diseases After Receiving Neoadjuvant Therapies to Breast Cancer. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Enzmann H, Brunnemann K, Iatropoulos M, Shpyleva S, Lukyanova N, Todor I, Moore M, Spicher K, Chekhun V, Tsuda H, Williams G. Inter-laboratory comparison of turkey in ovo carcinogenicity assessment (IOCA) of hepatocarcinogens. ACTA ACUST UNITED AC 2013; 65:729-35. [DOI: 10.1016/j.etp.2012.09.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2012] [Revised: 08/03/2012] [Accepted: 09/24/2012] [Indexed: 10/27/2022]
|
49
|
Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann Oncol 2013; 24:2594-2600. [PMID: 23899839 DOI: 10.1093/annonc/mdt293] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Even if detected at an early stage, a substantial number of lung cancers relapse after curative surgery. However, no method for distinguishing such tumors has yet been established. PATIENTS AND METHODS The copy number of the actinin-4 (ACTN4) gene was determined by fluorescence in situ hybridization on tissue microarrays comprising 543 surgically resected adenocarcinomas of the lung. RESULTS Amplification (an increase in the copy number by ≥ 2.0 fold) of the ACTN4 gene was detected in two of seven lung adenocarcinoma cell lines and 79 (15%) of 543 cases of pathological stage I-IV lung adenocarcinoma. Multivariate analysis revealed that ACTN4 gene amplification was the most significant independent factor associated with an extremely high risk of death (hazard ratio, 6.78; P = 9.48 × 10(-5), Cox regression analysis) among 290 patients with stage I lung adenocarcinoma. The prognostic significance of ACTN gene amplification was further validated in three independent cohorts totaling 1033 patients. CONCLUSIONS Amplification of the ACTN4 gene defines a small but substantial subset of patients with stage I lung adenocarcinoma showing a distinct outcome. Such patients require intensive medical attention and might benefit from postoperative adjuvant chemotherapy.
Collapse
Affiliation(s)
- R Noro
- Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo; Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo
| | - K Honda
- Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo
| | - K Tsuta
- Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo
| | - G Ishii
- Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Research Institute, Tokyo
| | - A M Maeshima
- Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo
| | - N Miura
- Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo
| | - K Furuta
- Division of Clinical Laboratories, National Cancer Center Hospital, Tokyo
| | - T Shibata
- Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo
| | - H Tsuda
- Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo
| | - A Ochiai
- Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Research Institute, Tokyo
| | - T Sakuma
- Mitsui Knowledge Industry, Tokyo
| | - N Nishijima
- Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo
| | - A Gemma
- Department of Internal Medicine, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Nippon Medical School, Tokyo
| | - H Asamura
- Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo
| | - K Nagai
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - T Yamada
- Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo.
| |
Collapse
|
50
|
Tsuda H, Saiki J. Gradual encoding and decay in visual working memory. J Vis 2013. [DOI: 10.1167/13.9.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|